Camp4 Therapeutics (CAMP) Company Report

Camp4 is advancing its flagship program, CMP-002, for SYNGAP1-related disorders, a genetic haploinsufficiency CNS disorder, with the goal of entering the clinic later this year (2026) after completing GLP-tox studies.
The company's financial runway extends to the end of 2027, not including a $50 million second tranche that will be unlocked upon regulatory approval to initiate its first-in-human study.
In December 2025, Camp4 announced a two-target deal with GSK for CNS and kidney targets, providing non-dilutive capital and leveraging its RAP platform.
Camp4 plans to announce at least one additional Developmental Epileptic Encephalopathies (DEE) program later this year (2026), building on its platform beyond SYNGAP.

19 hours ago

Transcript

Camp4 Provides Update on SYNGAP1 Program and Funding at J.P. Morgan Healthcare Conference

CAMP

New Projects/Investments

Guidance Update

Camp4 is advancing its flagship program, CMP-002, for SYNGAP1-related disorders, with GLP-tox studies concluding and plans to enter the clinic later in 2026.
The company utilizes its WRAP platform to selectively increase gene expression using antisense oligonucleotides, aiming to build a deep pipeline beyond SYNGAP1.
Camp4 announced a two-target deal with GSK in December 2025, which provides non-dilutive capital and expands the application of its platform.
The company is funded to the end of 2027, excluding an additional $50 million tranche that becomes available upon regulatory approval to initiate its first-in-human study.

20 hours ago

Transcript

Camp4 Provides Update on SYNGAP1 Program and Financial Outlook

CAMP

New Projects/Investments

Guidance Update

Camp4 is advancing its flagship program, CMP-002 for SYNGAP1-related disorders, an antisense oligonucleotide designed to increase SYNGAP protein levels, with GLP-tox studies concluding and clinical entry planned for later this year.
The company's WRAP platform is generating a deep pipeline, including plans to announce at least one additional developmental epileptic encephalopathy (DEE) program later this year.
A two-target deal with GSK was announced in December, providing non-dilutive capital and applying Camp4's platform to new CNS and kidney targets.
Camp4 is funded through the end of 2027, with an additional $50 million tranche contingent on regulatory approval for its first-in-human study later this year.

20 hours ago

Transcript

CAMP4 Therapeutics Corporation Announces Common Stock Offering

CAMP

CAMP4 Therapeutics Corporation entered into an underwriting agreement with Leerink Partners LLC for the issuance and sale of 5,000,000 shares of its common stock at an offering price of $6.00 per share.
The company estimates the net proceeds from this offering will be approximately $28.0 million after deducting underwriting discounts, commissions, and estimated offering expenses.
The closing of the offering is expected to take place on or about December 19, 2025.
The company, its executive officers, directors, and certain stockholders have agreed to a 60-day lock-up period following the date of the Underwriting Agreement, restricting the disposal of common stock.

Dec 18, 2025, 10:15 PM

8-K

CAMP4 Announces Pricing of Underwritten Offering

CAMP

CAMP4 Therapeutics (Nasdaq: CAMP) announced the pricing of its underwritten offering of common stock.
The offering consists of 5,000,000 shares priced at $6.00 per share, expected to generate $30.0 million in gross proceeds.
The company anticipates using the net proceeds primarily to support continued development activities for its product candidates and for general corporate purposes.
The offering is expected to close on or about December 19, 2025, and includes participation from new and existing investors such as Janus Henderson Investors, Coastlands Capital, EcoR1 Capital, Trails Edge Capital Partners, and Vivo Capital.

Dec 18, 2025, 12:10 PM

Press Release

CAMP4 Therapeutics Enters Strategic Collaboration with GSK

CAMP

New Projects/Investments

CAMP4 Therapeutics Corporation has entered into a strategic research, collaboration, and license agreement with GSK to identify and develop antisense oligonucleotide (ASO) drug candidates for neurodegenerative and kidney disease indications.
Under the terms of the agreement, CAMP4 will receive an upfront cash payment of $17.5 million.
CAMP4 is eligible to receive up to $440 million in development and commercial milestone payments, in addition to tiered royalties on future product sales.
CAMP4 will utilize its proprietary RAP Platform® to identify regulatory RNAs and generate ASO candidates, with GSK responsible for further development and commercialization.

Dec 18, 2025, 12:00 PM

8-K

Camp4 Provides Update on Lead Program CMP002 and Financial Outlook

CAMP

New Projects/Investments

Guidance Update

Camp4 is advancing CMP002 for Syngap1-related disorders, a haploinsufficiency affecting over 10,000 patients in the U.S. and globally. Preclinical data demonstrated full protein recovery in patient cells and reversal of cognitive issues in humanized mice.
The company initiated GLP-tox studies for CMP002 in Q3 2025 and anticipates entering the clinic as early as H2 2026.
Camp4 reported $75 million in cash at the end of Q3 2025, with an additional $50 million expected upon CTA or IND acceptance for CMP002. This funding is projected to comfortably last into 2027, covering the period until potential clinical proof-of-concept in a Phase 1/2 study for Syngap patients.
Camp4 is pausing investment in its CMP001 program for urea cycle disorders and is actively seeking a partner.

Dec 3, 2025, 9:00 PM

Transcript

Camp4 Provides Update on Lead Program CMP002, Financial Runway, and Partnership Strategy

CAMP

New Projects/Investments

Guidance Update

Camp4 is advancing its platform of regulatory RNA (regRNA) medicines, which use antisense oligonucleotides to upregulate gene expression, primarily targeting haploinsufficiencies within the central nervous system (CNS).
The company's lead program, CMP002 for Syngap1-related disorders, initiated GLP-tox studies in Q3 2025 and is projected to enter the clinic as early as H2 2026. Syngap1-related disorders are estimated to affect over 10,000 patients in the U.S. and globally.
Camp4 reported $75 million in cash at the end of Q3 (2025) and anticipates an additional $50 million upon CTA/IND acceptance for CMP002, which is expected to provide a cash runway into 2027 and through potential clinical proof of concept for CMP002.
The company is actively seeking a partner for its CMP001 program for urea cycle disorders to prioritize its genetic epilepsy pipeline and has an existing two-target discovery deal with BioMarin for targets outside the liver and CNS.

Dec 3, 2025, 9:00 PM

Transcript

CAMP4 Therapeutics Reports Q3 2025 Financial Results and Strategic Program Updates

CAMP

Earnings

New Projects/Investments

M&A

CAMP4 Therapeutics reported a net loss of $15.1 million for the third quarter ended September 30, 2025, and held $75.3 million in cash, cash equivalents, and marketable securities as of that date.
The company strengthened its balance sheet by securing an initial $50 million from a private placement, with potential proceeds up to $100 million, which is expected to extend its cash runway into 2027.
CAMP4 initiated GLP toxicology studies for CMP-002, its lead program for SYNGAP1-related disorders, with a Phase 1/2 clinical trial anticipated to begin as early as H2 2026.
Following favorable Phase 1 trial results for CMP-001, the company made a strategic decision to pursue partnerships for its continued development in urea cycle disorders.

Nov 6, 2025, 9:08 PM

8-K

CAMP's CORRIDOR Advances AI Operations Manager to Production

CAMP

Product Launch

CORRIDOR, a product line of CAMP Systems, has deployed its AI Operations Manager with ACI Jet following a successful pilot program.
The AI Operations Manager applies predictive intelligence to modernize maintenance planning and execution, aiming to enhance accuracy, efficiency, and profitability for service centers and MROs.
Early deployments have demonstrated measurable results, including up to 10% faster sales cycles, a 50% reduction in unpaid work, and cost savings of up to 20% through improved mechanic efficiency and optimized material planning.
ACI Jet confirmed that this technology is already creating a measurable impact across their operations by anticipating labor and parts needs, reducing variability, and improving turnaround times.